SK287153B6 - Hexahydrofuro[2,3-b]furan-3-yl-N-{3-[(1,3-benzodioxol-5- ylsulfonyl)(izobutyl)amino]1-benzyl-2-hydroxypropyl}karbamát, jeho použitie a farmaceutický prípravok s jeho obsahom - Google Patents

Hexahydrofuro[2,3-b]furan-3-yl-N-{3-[(1,3-benzodioxol-5- ylsulfonyl)(izobutyl)amino]1-benzyl-2-hydroxypropyl}karbamát, jeho použitie a farmaceutický prípravok s jeho obsahom Download PDF

Info

Publication number
SK287153B6
SK287153B6 SK570-2002A SK5702002A SK287153B6 SK 287153 B6 SK287153 B6 SK 287153B6 SK 5702002 A SK5702002 A SK 5702002A SK 287153 B6 SK287153 B6 SK 287153B6
Authority
SK
Slovakia
Prior art keywords
compound
carbamate
compounds
hiv
hydroxypropyl
Prior art date
Application number
SK570-2002A
Other languages
English (en)
Slovak (sk)
Other versions
SK5702002A3 (en
Inventor
Piet Tom Bert Paul Wigerinck
Guangyang Wang
Michael Eissenstat
John W. Erickson
Original Assignee
Tibotec Pharmaceuticals Ltd.
The Government Of The United States Of America, Represented By
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tibotec Pharmaceuticals Ltd., The Government Of The United States Of America, Represented By filed Critical Tibotec Pharmaceuticals Ltd.
Publication of SK5702002A3 publication Critical patent/SK5702002A3/sk
Publication of SK287153B6 publication Critical patent/SK287153B6/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
SK570-2002A 1999-10-06 2000-10-06 Hexahydrofuro[2,3-b]furan-3-yl-N-{3-[(1,3-benzodioxol-5- ylsulfonyl)(izobutyl)amino]1-benzyl-2-hydroxypropyl}karbamát, jeho použitie a farmaceutický prípravok s jeho obsahom SK287153B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15785099P 1999-10-06 1999-10-06
PCT/EP2000/009917 WO2001025240A1 (fr) 1999-10-06 2000-10-06 HEXAHYDROFURO'2,3-B! FURAN-3-YL-N- {3'(1,3-BENZODIOXOL-5-YLSULFONYL) (ISOBUTYL) AMINO! -1-BENZYL-2-HYDROXYPROPYL}CARBAMATE EN TANT QU'INHIBITEUR DE PROTEASE RETROVIRALE

Publications (2)

Publication Number Publication Date
SK5702002A3 SK5702002A3 (en) 2003-01-09
SK287153B6 true SK287153B6 (sk) 2010-01-07

Family

ID=22565540

Family Applications (1)

Application Number Title Priority Date Filing Date
SK570-2002A SK287153B6 (sk) 1999-10-06 2000-10-06 Hexahydrofuro[2,3-b]furan-3-yl-N-{3-[(1,3-benzodioxol-5- ylsulfonyl)(izobutyl)amino]1-benzyl-2-hydroxypropyl}karbamát, jeho použitie a farmaceutický prípravok s jeho obsahom

Country Status (26)

Country Link
US (2) US6649651B1 (fr)
EP (1) EP1222192B8 (fr)
JP (1) JP4951179B2 (fr)
KR (1) KR100792391B1 (fr)
CN (1) CN1191256C (fr)
AP (1) AP1459A (fr)
AT (1) ATE398623T1 (fr)
AU (1) AU781656B2 (fr)
BR (1) BR0014602A (fr)
CA (1) CA2386850C (fr)
CZ (1) CZ300031B6 (fr)
DE (1) DE60039244D1 (fr)
DK (1) DK1222192T3 (fr)
ES (1) ES2307533T3 (fr)
HK (1) HK1054746A1 (fr)
HU (1) HU228938B1 (fr)
IL (2) IL149005A0 (fr)
MX (1) MXPA02003607A (fr)
NO (1) NO327996B1 (fr)
NZ (1) NZ518580A (fr)
OA (1) OA12053A (fr)
PL (1) PL204924B1 (fr)
RU (1) RU2247123C2 (fr)
SK (1) SK287153B6 (fr)
WO (1) WO2001025240A1 (fr)
ZA (1) ZA200202655B (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ518580A (en) * 1999-10-06 2004-01-30 Us Gov Health & Human Serv Hexahydrofuro[2,3-B]furan-3-YL-N- {3-[1,3-benzodioxol-5-ylsulfonyl) (isobutyl) amino]-1-benzyl-2-hydroxypropyl} carbamate as retroviral protease inhibitor
CN100491360C (zh) * 2001-04-09 2009-05-27 泰博特克药品有限公司 广谱2-(取代的-氨基)-苯并唑磺酰胺hiv蛋白酶抑制剂
DE60234952D1 (de) * 2001-09-10 2010-02-11 Tibotec Pharm Ltd VERFAHREN ZUR HERSTELLUNG VON HEXAHYDROFUROc2,3-BÜFURAN-3-OL
US7285566B2 (en) * 2002-01-07 2007-10-23 Erickson John W Resistance-repellent retroviral protease inhibitors
EP1483254A4 (fr) * 2002-01-07 2005-06-08 Sequoia Pharmaceuticals Inhibiteurs de protease retrovirale anti-resistance
US7157489B2 (en) * 2002-03-12 2007-01-02 The Board Of Trustees Of The University Of Illinois HIV protease inhibitors
IL165043A0 (en) 2002-05-17 2005-12-18 Tibotec Pharm Ltd broadspectrum substituted benzisoxazole sulfonamide hiv protease inhibitors
KR101327772B1 (ko) * 2002-08-02 2013-11-11 얀센 알 앤드 디 아일랜드 광범위 2-아미노-벤조티아졸 설폰아미드 ｈｉｖ 프로테아제 저해제
EP1589018A4 (fr) 2002-12-27 2007-03-14 Sumitomo Chemical Co Procede de production d'un derive de d'hexahydrofuranol, intermediaire de celui-ci et procede de production correspondant
MXPA06010365A (es) * 2004-03-11 2007-05-04 Sequoia Pharmaceuticals Inc Inhibidores de proteasa retrovirales repelentes a la resistencia.
TWI383975B (zh) 2004-03-31 2013-02-01 Tibotec Pharm Ltd 製備（３Ｒ，３ａＳ，６ａＲ）六氫-呋喃并〔２，３-ｂ〕呋喃-３-醇之方法
KR100698291B1 (ko) * 2004-12-29 2007-03-22 엘지전자 주식회사 조명계
JP5260965B2 (ja) 2005-02-25 2013-08-14 テイボテク・フアーマシユーチカルズ プロテアーゼ阻害剤前駆体合成
EP3696171A1 (fr) 2006-07-07 2020-08-19 Gilead Sciences, Inc. Modulateurs de propriétés pharmacocinétiques d'agents thérapeutiques
US20090312318A1 (en) * 2006-07-24 2009-12-17 Desai Manoj C Therapeutic compounds and methods
CN102432621B (zh) 2006-11-09 2016-02-17 爱尔兰詹森科学公司 六氢呋喃并[2,3-b]呋喃-3-醇的制备方法
US9808527B2 (en) 2006-11-21 2017-11-07 Purdue Research Foundation Methods and compositions for treating HIV infections
ES2603617T3 (es) 2007-02-23 2017-02-28 Gilead Sciences, Inc. Moduladores de propiedades farmacocinéticas de la terapéutica
US7981929B2 (en) * 2007-03-16 2011-07-19 Sequoia Pharmaceuticals, Inc. Benzofuran derived HIV protease inhibitors
JP5393665B2 (ja) 2007-07-06 2014-01-22 ギリアード サイエンシーズ， インコーポレイテッド 治療剤の薬物動態特性の調整剤
EP2231628B1 (fr) 2008-01-04 2015-10-28 Gilead Sciences, Inc. Inhibiteurs du cytrochrome p450
US20110046199A1 (en) * 2008-01-17 2011-02-24 Purdue Research Foundation Small molecule inhibitors of hiv proteases
WO2010002994A1 (fr) 2008-07-01 2010-01-07 Purdue Research Foundation Inhibiteurs de protéase de vih-1 non peptidiques
US8501961B2 (en) 2008-07-09 2013-08-06 Purdue Research Foundation HIV protease inhibitors and methods for using
NZ600156A (en) 2009-12-21 2015-01-30 Janssen R & D Ireland Degradable removable implant for the sustained release of an active compound
EP2643326B1 (fr) 2010-11-23 2016-09-14 Mylan Laboratories, Limited Procédé pour la préparation de (3R, 3aS, 6aR)-hexahydrofuro[2,3-b]furan-3-ol
ES2657227T3 (es) 2012-08-09 2018-03-02 Sumitomo Chemical Company, Limited Método para producir un derivado de hexahidrofurofuranol
CN103664976B (zh) * 2013-12-12 2015-11-04 惠州市莱佛士制药技术有限公司 一种顺式六氢呋喃并[2,3-b]呋喃-3-醇的制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995006030A1 (fr) * 1993-08-24 1995-03-02 G.D. Searle & Co. Hydroxyethylamino-sulfonamides aptes a etre utilises comme inhibiteurs de protease retrovirale
JP3657002B2 (ja) * 1992-08-25 2005-06-08 ジー．ディー．サール アンド カンパニー レトロウイルスプロテアーゼ阻害剤として有用なα−およびβ−アミノ酸ヒドロキシエチルアミノスルホンアミド
IS2334B (is) * 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
US5723490A (en) * 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
UA49803C2 (uk) * 1994-06-03 2002-10-15 Дж.Д. Сьорль Енд Ко Спосіб лікування ретровірусних інфекцій
US5705500A (en) * 1995-03-10 1998-01-06 G.D. Searle & Co. Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors
US5691372A (en) * 1995-04-19 1997-11-25 Vertex Pharmaceuticals Incorporated Oxygenated-Heterocycle containing sulfonamide inhibitors of aspartyl protease
AU4828199A (en) 1998-06-23 2000-01-10 Board Of Trustees Of The University Of Illinois, The Multi-drug resistant retroviral protease inhibitors and associated methods
CA2336160C (fr) * 1998-06-23 2015-02-17 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Utilisation de composes pour traiter le vih
GB9815567D0 (en) * 1998-07-18 1998-09-16 Glaxo Group Ltd Antiviral compound
NZ518580A (en) * 1999-10-06 2004-01-30 Us Gov Health & Human Serv Hexahydrofuro[2,3-B]furan-3-YL-N- {3-[1,3-benzodioxol-5-ylsulfonyl) (isobutyl) amino]-1-benzyl-2-hydroxypropyl} carbamate as retroviral protease inhibitor

Also Published As

Publication number Publication date
AU7663800A (en) 2001-05-10
AU781656B2 (en) 2005-06-02
KR100792391B1 (ko) 2008-01-08
PL354351A1 (en) 2004-01-12
IL149005A (en) 2006-12-31
CZ20021419A3 (cs) 2002-10-16
CA2386850A1 (fr) 2001-04-12
CA2386850C (fr) 2010-03-30
DK1222192T3 (da) 2008-10-20
OA12053A (en) 2006-05-02
AP2002002472A0 (en) 2002-06-30
HK1054746A1 (en) 2003-12-12
RU2247123C2 (ru) 2005-02-27
US20050261364A1 (en) 2005-11-24
ES2307533T3 (es) 2008-12-01
US6649651B1 (en) 2003-11-18
CN1191256C (zh) 2005-03-02
IL149005A0 (en) 2002-11-10
EP1222192B1 (fr) 2008-06-18
CN1407987A (zh) 2003-04-02
ATE398623T1 (de) 2008-07-15
SK5702002A3 (en) 2003-01-09
DE60039244D1 (de) 2008-07-31
NO20021598D0 (no) 2002-04-04
WO2001025240A1 (fr) 2001-04-12
ZA200202655B (en) 2003-09-23
JP2003511383A (ja) 2003-03-25
HU228938B1 (hu) 2013-06-28
NO327996B1 (no) 2009-11-02
PL204924B1 (pl) 2010-02-26
MXPA02003607A (es) 2003-07-28
NZ518580A (en) 2004-01-30
NO20021598L (no) 2002-05-29
HUP0203130A2 (hu) 2003-01-28
HUP0203130A3 (en) 2005-01-28
EP1222192B8 (fr) 2008-10-01
AP1459A (en) 2005-08-22
JP4951179B2 (ja) 2012-06-13
CZ300031B6 (cs) 2009-01-14
EP1222192A1 (fr) 2002-07-17
KR20020067503A (ko) 2002-08-22
US7157495B2 (en) 2007-01-02
BR0014602A (pt) 2002-06-11

Similar Documents

Publication Publication Date Title
SK287153B6 (sk) Hexahydrofuro[2,3-b]furan-3-yl-N-{3-[(1,3-benzodioxol-5- ylsulfonyl)(izobutyl)amino]1-benzyl-2-hydroxypropyl}karbamát, jeho použitie a farmaceutický prípravok s jeho obsahom
TWI385173B (zh) 作為ｈｉｖ蛋白酶抑制劑之經取代的胺基苯基磺醯胺化合物
BG108309A (bg) Широкоспектърни 2-амино-бензоксазол- сулфонамидни инхибитори на hiv-протеази
KR100872029B1 (ko) 광범위 2-(치환된-아미노)-벤즈옥사졸 설폰아미드 ｈｉｖ프로테아제 저해제
CA2531766C (fr) Inhibiteurs de la penetration du virus vih
EA008594B1 (ru) 2-аминобензотиазолсульфонамидные ингибиторы протеазы вич широкого спектра действия
KR101302421B1 (ko) 광범위 치환된 벤즈이미다졸 설폰아미드 ｈｉｖ 프로테아제 저해제
KR101327772B1 (ko) 광범위 2-아미노-벤조티아졸 설폰아미드 ｈｉｖ 프로테아제 저해제
IL172935A (en) Inhibitors of HIV penetration

Legal Events

Date Code Title Description
PC4A Assignment and transfer of rights

Owner name: THE GOVERNMENT OF THE UNITED STATES OF AMERICA, ES

Free format text: FORMER OWNER: JANSSEN R&D IRELAND, EASTGATE, LITTLE ISLAND, CO CORK, IE; THE GOVERNMENT OF T HE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES; NATIONAL INSTITUTES OF HEALTH OFFICE OF T ECHNOLOGY TRANSFER, ROCKVILLE, MD, US

Effective date: 20161206

Owner name: JANSSEN SCIENCES IRELAND UC, EASTGATE, LITTLE , IE

Free format text: FORMER OWNER: JANSSEN R&D IRELAND, EASTGATE, LITTLE ISLAND, CO CORK, IE; THE GOVERNMENT OF T HE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES; NATIONAL INSTITUTES OF HEALTH OFFICE OF T ECHNOLOGY TRANSFER, ROCKVILLE, MD, US

Effective date: 20161206

Owner name: NATIONAL INSTITUTES OF HEALTH OFFICE OF TECHNO, US

Free format text: FORMER OWNER: JANSSEN R&D IRELAND, EASTGATE, LITTLE ISLAND, CO CORK, IE; THE GOVERNMENT OF T HE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES; NATIONAL INSTITUTES OF HEALTH OFFICE OF T ECHNOLOGY TRANSFER, ROCKVILLE, MD, US

Effective date: 20161206

TC4A Change of owner's name

Owner name: NATIONAL INSTITUTES OF HEALTH OFFICE OF T ECHN, US

Effective date: 20161206

Owner name: JANSSEN R&D IRELAND, EASTGATE, LITTLE ISLAND, , IE

Effective date: 20161206

Owner name: THE GOVERNMENT OF T HE UNITED STATES OF AMERIC, ES

Effective date: 20161206

MK4A Expiry of patent

Expiry date: 20201006